杨雯靖,史 琳,陈芋屹,等.从价值医疗视角探讨EGFR突变阳性晚期非小细胞肺癌一线EGFR-TKI的选择[J].肿瘤学杂志,2022,28(10):802-808.
从价值医疗视角探讨EGFR突变阳性晚期非小细胞肺癌一线EGFR-TKI的选择
Choice of First-line EGFR-TKI Therapy for EGFR-mutated Advanced Non-small Cell Lung Cancer from the Perspective of Value Medical Treatment
投稿时间:2022-07-13  
DOI:10.11735/j.issn.1671-170X.2022.10.B002
中文关键词:  表皮生长因子受体突变  表皮生长因子受体酪氨酸激酶抑制剂  非小细胞肺癌  价值医疗
英文关键词:epidermal growth factor receptor mutation  epidermal growth factor receptor tyrosine kinase inhibitor  non-small cell lung cancer  value medical
基金项目:国家重点研发计划(2018YFC1705101)
作者单位
杨雯靖 首都医科大学附属北京中医医院 
史 琳 首都医科大学附属北京中医医院 
陈芋屹 首都医科大学附属北京中医医院 
周 杰 首都医科大学附属北京中医医院 
摘要点击次数: 548
全文下载次数: 177
中文摘要:
      摘 要:肺癌的发病率和死亡率均居我国恶性肿瘤的首位,且以晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者占比最高。众多表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)被推荐用于表皮生长因子受体(epidermal growth factor receptor,EGFR)突变阳性晚期NSCLC的一线治疗,但指导个体化临床实践仍面临挑战。目前价值医疗相关的研究及实践正盛,全文尝试从价值医疗视角(有效性、安全性、可及性)探讨EGFR突变阳性晚期NSCLC个体化一线EGFR-TKI的选择,以期为指南指导下EGFR-TKI个体化应用及践行价值医疗服务提供参考。
英文摘要:
      Abstract: Both the incidence and mortality of lung cancer rank first among malignant tumors in China, and the proportion of advanced non-small cell lung cancer(NSCLC) is the highest. The epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKIs) are recommended for the first-line treatment of advanced NSCLC with EGFR mutations, but there are still challenges in guiding individua-lized clinical practice. At present, research and practice related to value medicine are flourishing. This article aims to explore the selection of the appropriate EGFR-TKIs for the first-line personalized treatment in advanced NSCLC with EGFR mutations from the perspective of value medicine in terms of effectiveness, safety, and accessibility;and also provides reference for the individualized application of EGFR-TKIs and the practice of valuable medical services under clinical guidelines.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器